Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 275-286 , June 2008

Arginine vasopressin in the treatment of vasodilatory septic shock

  • Cheryl L. Holmes, MD, FRCPC (Clinical Instructor)

      Affiliations

    • Tel.: +1 250 212 9450; Fax: +1 250 764 9083.
  • Keith R. Walley, MD, FRCPC (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Keith R. Walley, MD, UBC McDonald Research Laboratories, St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. Tel.: +604 806 8136; Fax: +604 806 8351.

References 

  1. Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: an evidence-based review. Critical Care Medicine. 2004;32(11 Suppl):S455–S465
  2. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. The New England Journal of Medicine. 2001;345(8):588–595
  3. Cowley AW, Cushman WC, Quillen EW, et al. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension. 1981;3(3 Pt 2):I93–I100
  4. Goetz KL, Bond GC, Smith WE. Effect of moderate hemorrhage in humans on plasma ADH and renin. Proceedings of the Society for Experimental Biology and Medicine. 1974;145(1):277–280
  5. Wilson MF, Brackett DJ, Tompkins P, et al. Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Advances in Shock Research. 1981;6:15–26
  6. Morales D, Madigan J, Cullinane S, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation. 1999;100(3):226–229
  7. Errington ML, Rocha e Silva M. The secretion and clearance of vasopressin during the development of irreversible haemorrhagic shock. The Journal of Physiology (London). 1971;217(1):43P–45P
  8. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95(5):1122–1125
  9. Reid IA. Role of vasopressin deficiency in the vasodilation of septic shock. Circulation. 1997;95(5):1108–1110
  10. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. The Journal of Thoracic and Cardiovascular Surgery. 1998;116(6):973–980
  11. Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997;96(9 Suppl):II-286–II-290
  12. Chen JM, Cullinane S, Spanier TB, et al. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation. 1999;100(19 Suppl):II244–II246
  13. Rosenzweig EB, Starc TJ, Chen JM, et al. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation. 1999;100(19 Suppl):II182–II186
  14. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96(3):576–582
  15. Morales DL, Garrido MJ, Madigan JD, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. The Annals of Thoracic Surgery. 2003;75(3):926–930
  16. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Critical Care Medicine. 2003;31(6):1752–1758
  17. Lin IY, Ma HP, Lin AC, et al. Low plasma vasopressin/norepinephrine ratio predicts septic shock. The American Journal of Emergency Medicine. 2005;23(6):718–724
  18. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. The New England Journal of Medicine. 2008;358(9):877–887
  19. Russell JA. Vasopressin in vasodilatory and septic shock. Current Opinion in Critical Care. 2007;13(4):383–391
  20. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Critical Care Medicine. 2002;30(3):497–500
  21. Garrard CS, Kontoyannis DA, Piepoli M. Spectral analysis of heart rate variability in the sepsis syndrome. Clinical Autonomic Research. 1993;3(1):5–13
  22. Day TA, Randle JC, Renaud LP. Opposing alpha- and beta-adrenergic mechanisms mediate dose-dependent actions of noradrenaline on supraoptic vasopressin neurones in vivo. Brain Research. 1985;358(1–2):171–179
  23. Reid IA. Role of nitric oxide in the regulation of renin and vasopressin secretion. Frontiers in Neuroendocrinology. 1994;15(4):351–383
  24. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1-receptor physiology. Critical Care. 2003;7(6):427–434
  25. Holmes CL, Granton JT, Landry DW. Science review: vasopressin and the cardiovascular system part 2-clinical physiology. Critical Care. 2004;8(1):15–23
  26. Wakatsuki T, Nakaya Y, Inoue I. Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery. The American Journal of Physiology. 1992;263(2 Pt 2):H491–H496
  27. Landry DW, Oliver JA. The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. The Journal of Clinical Investigation. 1992;89(6):2071–2074
  28. Salzman AL, Vromen A, Denenberg A, Szabo C. K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. The American Journal of Physiology. 1997;272(2 Pt 2):H688–H694
  29. Archer SL, Huang JM, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(16):7583–7587
  30. Bolotina VM, Najibi S, Palacino JJ, et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994;368(6474):850–853
  31. Kilbourn R. Nitric oxide synthase inhibitors – a mechanism-based treatment of septic shock. Critical Care Medicine. 1999;27(5):857–858
  32. Umino T, Kusano E, Muto S, et al. AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. The American Journal of Physiology. 1999;276(3 Pt 2):F433–F441
  33. Karmazyn M, Manku MS, Horrobin DF. Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. Endocrinology. 1978;102(4):1230–1236
  34. Noguera I, Medina P, Segarra G, et al. Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery. British Journal of Pharmacology. 1997;122(3):431–438
  35. Caramelo C, Okada K, Tsai P, et al. Interaction of arginine vasopressin and angiotensin II on Ca2+ in vascular smooth muscle cells. Kidney International. 1990;38(1):47–54
  36. Emori T, Hirata Y, Ohta K, et al. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension. 1991;18(2):165–170
  37. Iversen BM, Arendshorst WJ. ANG II and vasopressin stimulate calcium entry in dispersed smooth muscle cells of preglomerular arterioles. The American Journal of Physiology. 1998;274(3 Pt 2):F498–F508
  38. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Critical Care Medicine. 1997;25(8):1279–1282
  39. Argenziano M, Chen JM, Cullinane S, et al. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. The Journal of Heart and Lung Transplantation. 1999;18(8):814–817
  40. Dünser MW, Mayr AJ, Stallinger A, et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Medicine. 2002;28(6):746–751
  41. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107(18):2313–2319
  42. Dünser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesthesia and Analgesia. 2001;93(1):7–13
  43. Gold J, Cullinane S, Chen J, et al. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. The American Journal of Cardiology. 2000;85(4):506–508A511
  44. Gold JA, Cullinane S, Chen J, et al. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Critical Care Medicine. 2000;28(1):249–252
  45. Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Medicine. 2001;27(8):1416–1421
  46. Malay MB, Ashton RC, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. The Journal of Trauma. 1999;47(4):699–703[discussion 703–695]
  47. Morales DL, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. The Annals of Thoracic Surgery. 2000;69(1):102–106
  48. Holmes CL, Walley KR, Ayers D, et al. Septic shock mortality decreased over time during the Vasopressin And Septic Shock Trial (VASST). American Journal of Respiratory and Critical Care Medicine. 2007;175:A508;[abstract series]
  49. Gordon AC, Russell JA, Holmes CL, et al. The effect of vasopressin on acute renal failure in septic shock. American Journal of Respiratory and Critical Care Medicine. 2007;175:A596;[abstracts issue]
  50. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care. 2004;8(4):R204–R212
  51. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Critical Care Medicine. 2004;32(3):858–873
  52. Rhodes A, Bennett ED. Early goal-directed therapy: an evidence-based review. Critical Care Medicine. 2004;32(11 Suppl):S448–S450

☆ Support: Heart & Stroke Foundation of B.C. and Yukon. Keith R. Walley is a B.C. Lung Association/St. Paul's Hospital Foundation Scientist.

PII: S1521-6896(08)00026-8

doi: 10.1016/j.bpa.2008.03.002

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 275-286 , June 2008

Article Tools

* Image Usage & Resolution